Metformin Hydrochloride Lyrus Life Sciences (Metformin Hydrochloride)

The drug reduces hepatic glucose production by inhibiting mitochondrial complex I, lowers intestinal glucose absorption, and increases peripheral glucose uptake through activation of AMP‑activated protein kinase. These actions collectively enhance insulin sensitivity without stimulating insulin release.

The exact dose is individualized by the prescribing clinician based on the patient’s renal function, glycaemic targets, and tolerability. Starting doses are typically low and titrated upward as needed, but the specific regimen should be determined by a qualified healthcare professional.

Safety data in pregnancy and lactation are limited. Metformin is not classified as contraindicated, but clinicians must weigh potential benefits against unknown risks. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To place an enquiry, visit the product page on gnhindia.com, enter the required quantity, and submit the request. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metformin is a first‑line biguanide that lowers glucose without causing hypoglycaemia when used alone, unlike sulfonylureas or insulin. It also promotes modest weight loss, whereas some other agents may cause weight gain. Its safety profile and low cost make it a preferred initial therapy for many patients.

Store the product at room temperature, preferably below 25 °C, in the original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children. No special refrigeration is required for this oral formulation.

Metformin is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water. The formulation is designed for systemic absorption through the gastrointestinal tract.

The most critical adverse events are lactic acidosis, a rare but potentially fatal metabolic disturbance, and severe cutaneous reactions such as Stevens‑Johnson syndrome. Hepatic dysfunction can also occur. Patients should seek immediate medical attention if they experience unexplained fatigue, muscle pain, rapid breathing, or skin blistering.

Metformin is contraindicated in individuals with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known metabolic acidosis, acute or chronic liver disease, and in patients who have experienced lactic acidosis while on the drug. Caution is also advised for those with conditions predisposing to hypoxia.